Anti-VEGF: What It Is, How It Works, and What You Need to Know

When your body makes too much VEGF, a protein that tells blood vessels to grow. Also known as vascular endothelial growth factor, it’s meant to help heal wounds and build new tissue—but when it goes rogue, it feeds tumors and leaks fluid into the eye. That’s where anti-VEGF, a class of drugs designed to block this protein. Also known as VEGF inhibitors, they stop abnormal blood vessels from forming and leaking. These drugs don’t cure disease, but they slow it down—sometimes dramatically. In cancer, they starve tumors by cutting off their blood supply. In eye conditions like wet macular degeneration, they stop fluid from blurring your vision. You’ve probably heard of drugs like Avastin, Lucentis, or Eylea—they’re all anti-VEGF treatments.

Anti-VEGF isn’t just one thing. It’s a strategy used in different parts of the body, for different reasons. In cancer treatment, it’s often paired with chemotherapy or immunotherapy to make those therapies work better. For macular degeneration, it’s injected directly into the eye, usually every few months, and many patients regain lost vision. It’s not magic—side effects like eye pressure spikes or infection can happen—but for millions, it’s the difference between seeing and not seeing, living and just surviving. The science behind it is simple: no new blood vessels, no fuel for disease. That’s why researchers keep testing new versions, new delivery methods, and new combinations.

What you won’t find in every article is how personal this gets. One person gets anti-VEGF for ovarian cancer. Another for diabetic retinopathy. A third for a rare eye tumor. The drug is the same, but the impact? Totally different. That’s why the posts below cover everything from how these drugs interact with other meds to what patients actually experience week to week. You’ll see real stories about side effects, treatment schedules, and how people manage life while getting regular injections. There’s also info on newer options, cost challenges, and what’s coming next in 2025. This isn’t just a list of articles—it’s a roadmap for anyone living with or caring for someone using anti-VEGF therapy. What you read here might help you ask the right questions next time you talk to your doctor.

Age-Related Macular Degeneration: How Central Vision Loss Works and Why Anti-VEGF Treatments Are the Standard

Age-related macular degeneration causes central vision loss, especially in people over 65. Anti-VEGF injections are the standard treatment for wet AMD, helping to stop vision loss and sometimes improve sight. Early detection and consistent care make all the difference.

Full story